Details for New Drug Application (NDA): 081225
✉ Email this page to a colleague
NDA 081225 describes ADRUCIL, which is a drug marketed by Pharmacia And Upjohn and Teva Parenteral and is included in four NDAs. Additional details are available on the ADRUCIL profile page.
The generic ingredient in ADRUCIL is fluorouracil. There are fifteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fluorouracil profile page.
The generic ingredient in ADRUCIL is fluorouracil. There are fifteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fluorouracil profile page.
Summary for 081225
| Tradename: | ADRUCIL |
| Applicant: | Teva Parenteral |
| Ingredient: | fluorouracil |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 081225
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 50MG/ML | ||||
| Approval Date: | Aug 28, 1991 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
